Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

Stopped early · Not applicable

Conditions studied: Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Acute, Lymphoma, Low-Grade, Lymphoma, T-Cell, Lymphoma, B-Cell

In brief

High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.

Key facts

Study ID

NCT00038883

Run by

M.D. Anderson Cancer Center

People needed

19

Starts

2001-04-09

Expected to finish

2006-05-01

Last updated by the study team

2018-11-07

Who can join

Age: 15 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 15-65 years old
• B or T-cell lymphoid disease, not eligible for non-myeloablative transplantation.
• Patients in relapse after failing conventional chemotherapy.
• Patients with HLA-identical or one-antigen mismatched sibling, or a matched unrelated donor.
• Performance status </=2.

You may not qualify if…

• Past history of anaphylaxis following exposure to rat or mouse derived CDR-grafted humanized monoclonal antibodies.
• Less than 4 weeks since prior chemotherapy.
• Pregnancy or lactation.
• HIV or HTLV-I positivity.
• Serum creatinine >1.6 mg/dl or serum bilirubin >0.2 mg/dl unless due to tumor, SGPT >/= 2 x NI
• PFT-DCLO<50%, cardiac EF <50% of predicted levels.

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.